Results 141 to 150 of about 251,076 (337)

Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Extended‐release (ER) formulations of the stimulant methylphenidate are commonly used to treat attention‐deficit/hyperactivity disorder in both children and adults. Previous studies have shown that the clinical effectiveness of long‐acting methylphenidate formulations is closely tied to the drug's pharmacokinetic (PK) profile, highlighting the
Ann C. Childress   +2 more
wiley   +1 more source

Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Selective N‐methyl‐D‐aspartate receptor subunit 2b negative allosteric modulators (NR2B NAMs) are being explored as potential new treatment options for major depressive disorder (MDD). This Phase Ib, randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted in adults (N = 59) with moderate‐to‐severe MDD and insufficient response ...
Roger S. McIntyre   +9 more
wiley   +1 more source

Comparing Outcomes for Telehealth Versus In‐Person Family‐Based Treatment: A Retrospective Chart Review

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Telehealth services have become part of many eating disorder (ED) treatment settings; yet, few studies have examined the effectiveness of family‐based treatment (FBT) delivered via telehealth. This study compared in‐person and telehealth FBT in rates of weight restoration, treatment completion, and metrics of treatment progress, and ...
Catherine R. Drury   +20 more
wiley   +1 more source

From acute to chronic pain: tapentadol in the progressive stages of this disease entity [PDF]

open access: yes, 2017
OBJECTIVE: Chronic pain is now recognized as a neural disease, which results from a maladaptive functional and structural transformation process occurring over time. In its chronic phase, pain is not just a symptom but also a disease entity.
Coluzzi, Flaminia   +3 more
core  

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy